Abstract: A protection glass adapter for a surgical microscope has a first abutment surface which can be brought into contact with a corresponding second abutment surface of the microscope. The adapter has a guide opening for receiving a main objective. The guide opening is a truncated cone with a central axis. The greater diameter of the truncated cone is formed toward the first abutment surface. A positioning element of the adapter is rigid and arranged on the first abutment surface. The positioning element is received with form-fit engagement in a mating element on the surgical microscope. The adapter has a holding element. A holding force in the form of a magnetic force can be applied by the holding element parallel to the central axis between the adapter and the microscope.

Abstract: A protection glass adapter for a surgical microscope has a first abutment surface. The first abutment surface can be brought into contact with a corresponding second abutment surface of the microscope. The adapter has a guide opening for receiving a main objective. The guide opening is a truncated cone with a central axis. The greater diameter of the truncated cone is formed toward the first abutment surface. The adapter has a positioning element. The positioning element is rigid and is arranged on the first abutment surface or on the surface of the guide opening. The positioning element is suitable for being received with form-fit engagement in a mating element on the surgical microscope. The adapter has a holding element. A holding force can be applied by the holding element parallel to the central axis between the adapter and the microscope. The holding force is formed by magnetic force.

Abstract: The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, short interfering RNA (siRNA), short interfering nucleic acid (siNA), and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 (VEGFR1) and/or KDR (VEGFR2). Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and other conditions associated with VEGF-R are provided, optionally in conjunction with other therapeutic agents such as interferons.

Abstract: The present invention is directed to compositions and methods for affecting metallocorrinoid uptake. The compositions and methods of the present invention are particularly useful in enhancing the uptake or availability of biologically active metallocorrinoids (e.g. cobalamin and its analogs). The present invention is particularly useful in the treatment or prevention of conditions that result from low expression or activity of proteins involved in the processing of metallocorrinoids, as well as in conditions which would benefit from enhanced uptake or availability of cobalamin or its biologically active analogs of cobalamin (e.g. cobalamin drug conjugates).

Abstract: The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, short interfering RNA (siRNA), short interfering nuleic acid (siNA), and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 (VEGFR1) and/or KDR (VEGFR2). Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and other conditions associated with VEGF-R are provided, optionally in conjunction with other therapeutic agents such as interferons.